Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases

Immunology Letters

Volumn 118, Issue 1, 2008, Pages 36-43

  Molling, Johan W ^a   Moreno, María ^a   de Groot, Jan ^a   van der Vliet, Hans J J ^a   von Blomberg, B Mary E ^a   van den Eertwegh, Alfons J M ^a   Scheper, Rik J ^a   Bontkes, Hetty J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adoptive transfer; Mouse; Natural Killer T cell lines; Tumor immunity

Indexed keywords

ALPHA GALACTOSYLCERAMIDE;

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN B16.F10; CYTOKINE RELEASE; DENDRITIC CELL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA CELL; METASTASIS; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TUMOR MODEL;

ANIMALS; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 44149084203     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2008.02.007     Document Type: Article

References (44)

1. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., and Baxter A.G. NKT cells: facts, functions and fallacies. Immunol Today 21 11 (2000) 573-583
2. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 5343 (1997) 1626-1629
3. Spada F.M., Koezuka Y., and Porcelli S.A. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188 8 (1998) 1529-1534
4. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 5702 (2004) 1786-1789
5. Mattner J., Debord K.L., Ismail N., Goff R.D., Cantu III C., Zhou D., et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 7032 (2005) 525-529
6. Wu D., Xing G.W., Poles M.A., Horowitz A., Kinjo Y., Sullivan B., et al. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci USA 102 5 (2005) 1351-1356
7. Kinjo Y., Tupin E., Wu D., Fujio M., Garcia-Navarro R., Benhnia M.R., et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol 7 9 (2006) 978-986
8. Kitamura H., Ohta A., Sekimoto M., Sato M., Iwakabe K., Nakui M., et al. Alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol 199 1 (2000) 37-42
9. Hermans I.F., Silk J.D., Gileadi U., Salio M., Mathew B., Ritter G., et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171 10 (2003) 5140-5147
10. Fujii S., Shimizu K., Smith C., Bonifaz L., and Steinman R.M. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 2 (2003) 267-279
11. Smyth M.J., Wallace M.E., Nutt S.L., Yagita H., Godfrey D.I., and Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 201 12 (2005) 1973-1985
12. Yu K.O., and Porcelli S.A. The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy. Immunol Lett 100 1 (2005) 42-55
13. van der Vliet H.J., Molling J.W., von Blomberg B.M., Nishi N., Kolgen W., van den Eertwegh A.J., et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 112 1 (2004) 8-23
14. Brutkiewicz R.R., and Sriram V. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol 41 3 (2002) 287-298
15. Chamoto K., Takeshima T., Kosaka A., Tsuji T., Matsuzaki J., Togashi Y., et al. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo. Immunol Lett 95 1 (2004) 5-11
16. Crowe N.Y., Smyth M.J., and Godfrey D.I. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196 1 (2002) 119-127
17. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191 4 (2000) 661-668
18. Takeda K., Hayakawa Y., Atsuta M., Hong S., Van Kaer L., Kobayashi K., et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol 12 6 (2000) 909-914
19. Taniguchi M., Seino K., and Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol 4 12 (2003) 1164-1165
20. Akutsu Y., Nakayama T., Harada M., Kawano T., Motohashi S., Shimizu E., et al. Expansion of lung Valpha14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells. Jpn J Cancer Res 93 4 (2002) 397-403
21. Nakui M., Ohta A., Sekimoto M., Sato M., Iwakabe K., Yahata T., et al. Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells. Clin Exp Metastasis 18 2 (2000) 147-153
22. Nakagawa R., Nagafune I., Tazunoki Y., Ehara H., Tomura H., Iijima R., et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 166 11 (2001) 6578-6584
23. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Sato H., et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 95 10 (1998) 5690-5693
24. Nakui M., Iwakabe K., Ohta A., Sekimoto M., Sato M., Makuuchi H., et al. Natural killer T cell ligand alpha-galactosylceramide inhibited lymph node metastasis of highly metastatic melanoma cells. Jpn J Cancer Res 90 8 (1999) 801-804
25. Molling J.W., Kolgen W., van der Vliet H.J., Boomsma M.F., Kruizenga H., Smorenburg C.H., et al. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116 1 (2005) 87-93
26. Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S., Dhodapkar K.M., et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197 12 (2003) 1667-1676
27. Motohashi S., Kobayashi S., Ito T., Magara K.K., Mikuni O., Kamada N., et al. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients. Int J Cancer 102 2 (2002) 159-165
28. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167 7 (2001) 4046-4050
29. Molling J.W., Langius J.A., Langendijk J.A., Leemans C.R., Bontkes H.J., van der Vliet H.J., et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25 7 (2007) 862-868
30. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., et al. A Phase i study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8 12 (2002) 3702-3709
31. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., et al. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103 2 (2004) 383-389
32. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M., et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11 5 (2005) 1910-1917
33. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201 9 (2005) 1503-1517
34. Motohashi S., Ishikawa A., Ishikawa E., Otsuji M., Iizasa T., Hanaoka H., et al. A phase I study of in vitro expanded natural killer t cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res (2006)
35. van der Vliet H.J., Molling J.W., Nishi N., Masterson A.J., Kolgen W., Porcelli S.A., et al. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res 63 14 (2003) 4101-4106
36. Molling J.W., Moreno M., van der Vliet H.J., von Blomberg B.M., van den Eertwegh A.J., Scheper R.J., et al. Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. J Immunol Methods 322 1/2 (2007) 70-81
37. Foti M., Granucci F., Aggujaro D., Liboi E., Luini W., Minardi S., et al. Upon dendritic cell (DC) activation chemokines and chemokine receptor expression are rapidly regulated for recruitment and maintenance of DC at the inflammatory site. Int Immunol 11 6 (1999) 979-986
38. Wilson M.T., Johansson C., Olivares-Villagomez D., Singh A.K., Stanic A.K., Wang C.R., et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 100 19 (2003) 10913-10918
39. Liu K., Idoyaga J., Charalambous A., Fujii S., Bonito A., Mordoh J., et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 202 11 (2005) 1507-1516
40. Hayakawa Y., Takeda K., Yagita H., Smyth M.J., Van Kaer L., Okumura K., et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100 5 (2002) 1728-1733
41. Ting C.C., Wang J., and Yang Y. Interleukin-2 and interleukin-7 augment the cytolytic activity and expand the antitumor killing spectrum of alpha CD3-induced activated killer cells: potential use in the immunotherapy of non-immunogenic tumors. Cancer Immunol Immunother 43 5 (1996) 283-292
42. Crowe N.Y., Coquet J.M., Berzins S.P., Kyparissoudis K., Keating R., Pellicci D.G., et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202 9 (2005) 1279-1288
43. Shin T., Nakayama T., Akutsu Y., Motohashi S., Shibata Y., Harada M., et al. Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Valpha14 NKT cells. Int J Cancer 91 4 (2001) 523-528
44. Brossay L., Chioda M., Burdin N., Koezuka Y., Casorati G., Dellabona P., et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188 (1998) 1521-1528